JP2022538690A5 - - Google Patents

Info

Publication number
JP2022538690A5
JP2022538690A5 JP2022500512A JP2022500512A JP2022538690A5 JP 2022538690 A5 JP2022538690 A5 JP 2022538690A5 JP 2022500512 A JP2022500512 A JP 2022500512A JP 2022500512 A JP2022500512 A JP 2022500512A JP 2022538690 A5 JP2022538690 A5 JP 2022538690A5
Authority
JP
Japan
Prior art keywords
alkyl
alkylene
pharmaceutically acceptable
independently
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022500512A
Other languages
English (en)
Japanese (ja)
Other versions
JP7622031B2 (ja
JP2022538690A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/040891 external-priority patent/WO2021007160A1/en
Publication of JP2022538690A publication Critical patent/JP2022538690A/ja
Publication of JP2022538690A5 publication Critical patent/JP2022538690A5/ja
Priority to JP2025005471A priority Critical patent/JP2025063195A/ja
Application granted granted Critical
Publication of JP7622031B2 publication Critical patent/JP7622031B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022500512A 2019-07-05 2020-07-06 トランス-シクロオクテン生体直交型薬剤並びに癌及び免疫療法における使用 Active JP7622031B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025005471A JP2025063195A (ja) 2019-07-05 2025-01-15 トランス-シクロオクテン生体直交型薬剤並びに癌及び免疫療法における使用

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962871051P 2019-07-05 2019-07-05
US62/871,051 2019-07-05
US202062971196P 2020-02-06 2020-02-06
US62/971,196 2020-02-06
US202062981401P 2020-02-25 2020-02-25
US62/981,401 2020-02-25
PCT/US2020/040891 WO2021007160A1 (en) 2019-07-05 2020-07-06 Trans-cyclooctene bioorthogonal agents and uses in cancer and immunotherapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025005471A Division JP2025063195A (ja) 2019-07-05 2025-01-15 トランス-シクロオクテン生体直交型薬剤並びに癌及び免疫療法における使用

Publications (3)

Publication Number Publication Date
JP2022538690A JP2022538690A (ja) 2022-09-05
JP2022538690A5 true JP2022538690A5 (https=) 2023-08-03
JP7622031B2 JP7622031B2 (ja) 2025-01-27

Family

ID=71842858

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022500512A Active JP7622031B2 (ja) 2019-07-05 2020-07-06 トランス-シクロオクテン生体直交型薬剤並びに癌及び免疫療法における使用
JP2025005471A Pending JP2025063195A (ja) 2019-07-05 2025-01-15 トランス-シクロオクテン生体直交型薬剤並びに癌及び免疫療法における使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025005471A Pending JP2025063195A (ja) 2019-07-05 2025-01-15 トランス-シクロオクテン生体直交型薬剤並びに癌及び免疫療法における使用

Country Status (8)

Country Link
US (1) US20220259254A1 (https=)
EP (1) EP3993834A1 (https=)
JP (2) JP7622031B2 (https=)
CN (1) CN114340680A (https=)
AU (1) AU2020310853A1 (https=)
CA (1) CA3145889A1 (https=)
IL (1) IL289596A (https=)
WO (1) WO2021007160A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116056765A (zh) 2020-08-07 2023-05-02 坦伯公司 反式环辛烯生物正交剂及在癌症和免疫疗法中的用途
WO2023077129A1 (en) 2021-10-29 2023-05-04 Tambo, Inc. Tetrazine conjugates for in vivo targeted delivery of a payload
CN121419788A (zh) 2023-05-04 2026-01-27 坦博公司 用于体内递送有效载荷的基于四嗪的靶向剂
EP4713022A1 (en) 2023-05-18 2026-03-25 Tambo, Inc. Trans-cyclooctene-modified targeted protein degrader conjugates
KR20260046464A (ko) * 2023-07-27 2026-04-07 베락사 바이오테크 게엠베하 친수성 트랜스-시클로옥텐(hyTCO) 화합물, 이를 포함하는 구조체 및 접합체
WO2025059685A1 (en) 2023-09-15 2025-03-20 Tambo, Inc. Methods for in vivo targeted delivery of a payload
CN117599001B (zh) * 2023-11-29 2025-05-09 南京鼓楼医院 一种生物正交Janus微球及其制备方法和应用
CN119424649A (zh) * 2024-02-29 2025-02-14 中山大学附属第一医院 假体周围感染治疗靶点及其应用
WO2025231424A1 (en) * 2024-05-02 2025-11-06 Arizona Board Of Regents On Behalf Of Arizona State University Procapped mrna for targeted cell translation

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL73534A (en) 1983-11-18 1990-12-23 Riker Laboratories Inc 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
US7919079B2 (en) 2006-03-31 2011-04-05 Biosante Pharmaceuticals, Inc. Cancer immunotherapy compositions and methods of use
EP2017281A4 (en) 2006-04-14 2012-03-14 Kyowa Hakko Kirin Co Ltd AGONISTS AT TOLL-LIKE RECEPTOR 9
KR20100053598A (ko) 2007-08-01 2010-05-20 이데라 파마슈티칼즈, 인코포레이티드 Tlr9의 신규한 합성 효능제
EP2391718A2 (en) 2009-01-30 2011-12-07 Idera Pharmaceuticals, Inc. Novel synthetic agonists of tlr9
EP3195868A3 (en) * 2010-10-01 2017-08-02 VentiRx Pharmaceuticals, Inc. Therapeutic use of a tlr agonist and combination therapy
US20150297741A1 (en) * 2012-11-22 2015-10-22 Tagworks Pharmaceuticals B.V. Bio-orthogonal drug activation
PE20160080A1 (es) 2013-05-18 2016-02-21 Aduro Biotech Inc Composiciones y metodos para activar la senalizacion que depende del estimulador del gen de interferon
WO2014189806A1 (en) 2013-05-18 2014-11-27 Aduro Biotech, Inc. Compositions and methods for inhibiting "stimulator of interferon gene" dependent signalling
ES2966631T3 (es) 2013-06-19 2024-04-23 Univ California Estructuras químicas para el suministro localizado de agentes terapéuticos
US10046002B2 (en) 2013-08-02 2018-08-14 Syntrix Biosystems Inc. Method for treating cancer using chemokine antagonists
JP2016538344A (ja) 2013-11-19 2016-12-08 ザ・ユニバーシティ・オブ・シカゴThe University Of Chicago 癌処置としてのstingアゴニストの使用
HUE045065T2 (hu) 2014-01-31 2019-12-30 Novartis Ag TIM-3 antitest molekulák és felhasználásaik
KR102442436B1 (ko) 2014-03-14 2022-09-15 노파르티스 아게 Lag-3에 대한 항체 분자 및 그의 용도
CN106659796B (zh) 2014-03-14 2021-04-30 加利福尼亚大学董事会 Tco缀合物和治疗剂递送方法
CR20160564A (es) 2014-06-04 2017-01-20 Glaxosmithkline Ip Dev Ltd Dinucleótidos cíclicos como moduladores de sting
GB201501462D0 (en) 2015-01-29 2015-03-18 Glaxosmithkline Ip Dev Ltd Novel compounds
EA035817B1 (ru) 2015-03-10 2020-08-14 Адуро Байотек, Инк. Композиции и способы для активации сигналинга, зависимого от "гена стимулятора интерферона"
KR102779525B1 (ko) 2015-05-29 2025-03-12 다이나박스 테크놀로지 코퍼레이션 폐암을 치료하기 위한 폴리뉴클레오티드 Toll-유사 수용체 9 아고니스트의 폐내 투여
US10532056B2 (en) * 2015-06-29 2020-01-14 Verastem, Inc. Therapeutic compositions, combinations, and methods of use
KR102222186B1 (ko) 2015-08-13 2021-03-03 머크 샤프 앤드 돔 코포레이션 Sting 효능제로서 시클릭 디-뉴클레오티드 화합물
WO2017044983A1 (en) * 2015-09-10 2017-03-16 Shasqi, Inc. Bioorthogonal compositions
JP2018534295A (ja) 2015-10-28 2018-11-22 アドゥロ バイオテック,インク. 「インターフェロン遺伝子刺激因子」依存性シグナル伝達を活性化するための組成物および方法
CN107849084B (zh) 2015-12-03 2021-09-14 葛兰素史密斯克莱知识产权发展有限公司 作为sting调节剂的环状嘌呤二核苷酸
KR102789862B1 (ko) 2016-01-11 2025-04-03 인네이트 튜머 이뮤니티, 인코포레이티드 Sting 활성과 연관된 상태 예컨대 암의 치료를 위한 시클릭 디뉴클레오티드
NZ746112A (en) 2016-03-18 2023-01-27 Immune Sensor Llc Cyclic di-nucleotide compounds and methods of use
EP3507367A4 (en) 2016-07-05 2020-03-25 Aduro BioTech, Inc. CYCLIC DINUCLEOTID COMPOUNDS WITH INCLUDED NUCLEIC ACIDS AND USES THEREOF
IL264049B2 (en) 2016-07-06 2023-11-01 Sperovie Biosciences Inc Compounds, preparations and methods for treating the disease
WO2018009652A1 (en) 2016-07-06 2018-01-11 Sperovie Biosciences, Inc. Compounds, compositions, and methods for the treatment of disease
CN109715202A (zh) 2016-07-15 2019-05-03 斯必乐维生物科学公司 用于治疗疾病的化合物、组合物和方法
WO2018013887A1 (en) 2016-07-15 2018-01-18 Sperovie Biosciences, Inc. Compounds, compositions, and methods for the treatment of disease
CN109790220A (zh) 2016-08-25 2019-05-21 豪夫迈·罗氏有限公司 与巨噬细胞激活剂组合的抗csf-1r抗体的间歇给药
US10537590B2 (en) 2016-09-30 2020-01-21 Boehringer Ingelheim International Gmbh Cyclic dinucleotide compounds
PT3523287T (pt) 2016-10-04 2021-10-06 Merck Sharp & Dohme Compostos de benzo[b]tiofeno como agonistas de sting
EP3532505A4 (en) 2016-10-25 2019-12-25 Urogen Pharma Ltd. BODY CAVES IMMUNODULATING TREATMENTS
JOP20170188A1 (ar) 2016-11-25 2019-01-30 Janssen Biotech Inc ثنائي النوكليوتيدات الحلقية كمنبهات ستينغ (sting)
PE20210255A1 (es) 2016-12-01 2021-02-10 Takeda Pharmaceuticals Co Dinucleotido ciclico como agonistas de sting (estimulador de genes de interferon)
AU2017378782A1 (en) 2016-12-20 2019-07-04 Merck Sharp & Dohme Corp. Combinations of PD-1 antagonists and cyclic dinucleotide sting agonists for cancer treatment
WO2018118665A1 (en) 2016-12-20 2018-06-28 Merck Sharp & Dohme Corp. Cyclic dinucleotide sting agonists for cancer treatment
US11021511B2 (en) 2017-01-27 2021-06-01 Janssen Biotech, Inc. Cyclic dinucleotides as sting agonists
CN110234403A (zh) 2017-01-27 2019-09-13 詹森生物科技公司 作为sting激动剂的环状二核苷酸
JOP20190218A1 (ar) 2017-03-22 2019-09-22 Boehringer Ingelheim Int مركبات ثنائية النيوكليوتيدات حلقية معدلة
AU2018250312C1 (en) * 2017-04-07 2024-08-22 Tambo, Inc. Bioorthogonal compositions
UY37695A (es) 2017-04-28 2018-11-30 Novartis Ag Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
US11466047B2 (en) 2017-05-12 2022-10-11 Merck Sharp & Dohme Llc Cyclic di-nucleotide compounds as sting agonists
US20200138827A1 (en) 2017-06-22 2020-05-07 Curadev Pharma Limited Small molecule modulators of human sting
UA125730C2 (uk) 2017-06-22 2022-05-25 Курадев Фарма Лімітед Низькомолекулярні модулятори sting людини
WO2018234807A1 (en) 2017-06-22 2018-12-27 Curadev Pharma Limited Heterocyclic small molecule modulators of human sting
JP2020530838A (ja) 2017-08-04 2020-10-29 メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. がん治療のためのベンゾ[b]チオフェンSTINGアゴニスト
WO2019046511A1 (en) 2017-08-31 2019-03-07 Sperovie Biosciences, Inc. COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASE
US11584774B2 (en) 2017-09-11 2023-02-21 F-star Therapeutics, Inc. Compounds, compositions, and methods for the treatment of disease
US11707531B2 (en) 2017-09-11 2023-07-25 F-star Therapeutics, Inc. Compounds, compositions, and methods for the treatment of disease
AR114990A1 (es) 2017-11-02 2020-11-18 Alios Biopharma Inc Constructos de oligonucleótidos y usos de los mismos
KR20200098511A (ko) 2017-11-10 2020-08-20 다케다 야쿠힌 고교 가부시키가이샤 Sting 조절제 화합물, 및 제조 및 사용 방법
CN111712509A (zh) 2017-12-15 2020-09-25 詹森生物科技公司 作为sting激动剂的环状二核苷酸
CR20200260A (es) 2017-12-15 2020-08-01 Bayer Animal Health Gmbh Composiciones inmunoestimulantes
US20190185509A1 (en) 2017-12-20 2019-06-20 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'2' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
WO2019123339A1 (en) 2017-12-20 2019-06-27 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
EP3727401A4 (en) 2017-12-20 2022-04-06 Merck Sharp & Dohme Corp. CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS
EP3728283B1 (en) 2017-12-20 2023-11-22 Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. 3'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein

Similar Documents

Publication Publication Date Title
JP2022538690A5 (https=)
JP6522056B2 (ja) mTORインヒビター、ハーセプチン、および/またはHKI−272の抗悪性腫瘍性組み合わせ
EP1364628B1 (en) Coated medical devices
JP5566431B2 (ja) 医療装置に結合した改善された疎水性を有した薬剤
US8470357B2 (en) Methods of treatment with Syk inhibitors
CN1326577C (zh) N-{5-[4-(4-甲基-哌嗪-1-基甲基)-苯甲酰氨基]-2-甲基苯基}-4-(3-吡啶基)-2-嘧啶-胺涂层的支架
CN101947351A (zh) 雷帕霉素容器洗脱支架
JP2003533495A (ja) 脈管の病気の治療のための配給システム
JP2020516621A5 (https=)
JP2003533493A (ja) 再狭窄の予防に有効な薬剤の組み合わせ
EP1465624A1 (en) Drug delivery systems for the prevention and treatment of vascular diseases comprising rapamycin and derivatives thereof
EP2062580A1 (en) Use of dipyridamole or mopidamole for treatment and prevention of thromboembolic diseases and disorders caused by excessive formation of thrombin and/or by elevated expression of trombin receptors
CN101874907A (zh) 双药物支架
CA2690119A1 (en) Use of taci-ig fusion protein such as atacicep for the manufacture of a medicament for treating lupus erythematosus
CN1747734A (zh) 潘生丁或单哌潘生丁在治疗和预防mmp-9-依赖性疾病中的用途
JPWO2015125641A1 (ja) 高分子化カンプトテシン誘導体及び高分子化hsp90阻害剤誘導体を含む医薬組成物
Richardson et al. Cancer Chemotherapy & Biotherapy: Principles & Practices
AU2009201507A1 (en) Drug delivery systems for the prevention and treatment of vascular diseases comprising rapamycin and derivatives thereof
AU2013204788A1 (en) Antineoplastic combinations with mtor inhibitor, herceptin, and/or hki-272